0001209191-21-060638.txt : 20211015 0001209191-21-060638.hdr.sgml : 20211015 20211015190226 ACCESSION NUMBER: 0001209191-21-060638 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211014 FILED AS OF DATE: 20211015 DATE AS OF CHANGE: 20211015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lebwohl David CENTRAL INDEX KEY: 0001810882 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 211327023 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS, INC. STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-14 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001810882 Lebwohl David C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Medical Officer Common Stock 2021-10-14 4 M 0 2400 12.62 A 11114 D Common Stock 2021-10-14 4 S 0 551 126.92 D 10563 D Common Stock 2021-10-14 4 S 0 849 127.81 D 9714 D Common Stock 2021-10-14 4 S 0 225 129.01 D 9489 D Common Stock 2021-10-14 4 S 0 525 129.83 D 8964 D Common Stock 2021-10-14 4 S 0 250 130.47 D 8714 D Stock Option (right to buy) 12.62 2021-10-14 4 M 0 2400 0.00 D 2030-04-30 Common Stock 2400 182477 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.345 to $127.32, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.38 to $128.26, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.40 to $129.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.41 to $130.09, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.425 to $130.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 70,833 shares as of October 14, 2021. /s/James Basta, Attorney-in-fact 2021-10-15